Emergingby GlyphFirst randomized Phase 2 data for JNJ-1900 in stage 3 lung cancer
Johnson & Johnson presented the data at the 2026 European Lung Cancer Conference.
Nanotechnologysec.gov
Johnson & Johnson
Public companyUS1 field
Where it works
| Technology | ||
|---|---|---|
| NanotechnologyLicenses and runs global development of Nanobiotix's NBTXR3 nanoparticle as JNJ-1900. | Licenses and runs global development of Nanobiotix's NBTXR3 nanoparticle as JNJ-1900. | sec.gov |
Events
European regulators reclassify NBTXR3 from device to medicinal product
The change aligns the nanoparticle's status with the US and other major markets.
Nanotechnologysec.gov
Nanobiotix amends its NBTXR3 licensing deal with Johnson & Johnson
The amendment strengthens Nanobiotix finances and extends cash visibility to mid-2026.
Nanotechnologysec.gov
About
- Source
- sec.gov (filing, added by seed)
- First seen
- Sep 25, 2026
- Last seen
- Oct 13, 2026
- Across Glyph
- Johnson & Johnson on Companies
Johnson & Johnson
Joined in Nanotechnology. Licenses and runs global development of Nanobiotix's NBTXR3 nanoparticle as JNJ-1900.
Johnson & Johnson
Added in Nanotechnology. Licenses and runs global development of Nanobiotix's NBTXR3 nanoparticle as JNJ-1900.